Research on the Impact of the Centralized Drug Procurement Policy on China’s Pharmaceutical Enterprises

Abstract

Objective To analyze the impact of the centralized drug procurement policy on pharmaceutical enterprises, and put forward some suggestions for improving China’s centralized drug procurement policy. Methods Through literature analysis and comparative research, the relevant policies and implementation effects from the “4 + 7” drug procurement pilot to the seventh batch of volume procurement were sorted out, and the impact of the procurement policy on pharmaceutical enterprises was analyzed. Results and Conclusion The centralized drug procurement policy has continuously improved the enthusiasm of enterprises to participate in bidding, and the consistency evaluation work has been carried out well. However, there are also some problems, such as the reduction of enterprise profits, the difficulty of enterprise operation, the decline in the quality of winning drugs, and the insufficient innovation ability and the supply capacity of enterprises. In this regard, enterprises should reasonably control the cost of drugs to ensure the stable supply of winning drugs. Besides, enterprises should create brand effect for their timely transformation and development. While strengthening pharmaceutical innovation, they can change from low-level generic drug production to R&D innovation. The government should pay close attention to the impact of centralized procurement on the quality and efficiency of enterprise drugs. For instance, the government should improve the pricing rules for drug procurement and increase supervision of drug quality and supply. At the same time, it should give certain policy and financial support to enterprises’ technological innovation and talent introduction.

Keywords

pharmaceutical collection / purchase of pharmaceutical products in quantity / procurement policy

References

[1] Shanghai Sunshine Pharmaceutical Procurement Network. On the state organization of centralized drug procurement pilot Q&A[EB/OL]. (2018-12-08)[2021-12-22]. https://www.smpaa.cn/gjsdcg/2018/12/08/8534.shtml.

[2] General Office of the State Council. Opinions of the General Office of the State Council on Promoting the Normalization and Institutionalization of the Centralized Quantity Procurement of Drugs (Guo Ban Fa [2021] No. 2) Government Information Disclosure Column[EB/OL].(2021-01-28)[2022-01-22]. http://www.gov.cn/zhengce/content/2021-01/28/content_5583305.html.

[3] Chang Feng, Li Yiren. Analysis of the effectiveness of pharmaceutical procurement reform and research on problems in the new era[J]. China Medical Insurance, 2020 (7): 65-69.

[4] Shanghai Sunshine Pharmaceutical Procurement Network. Announcement of the Office of Joint Procurement of Centralized Procurement and Use of Drugs organized by the State on the issuance of the “National Document on Centralized Procurement of Drugs” (GY-YD2019-2) [EB/OL]. (2019-12-29)[2021-12-22]. https://www.smpaa.cn/gjsdcg/2019/12/29/9205.shtml.

[5] Li Aohua. collection official announcement in history! Anti-cancer drug price reduction of 90%, Hengrui Medicine heavyweight products unexpectedly lost - focus on interpretation - Guangxi Leju[EB/OL]. (2021-06-23)[2021-12-22]. http://www.leju.com.

[6] Li Xiaoxiao. The largest collection of bids in history:1 aborted, the average reduction of 56%, ten foreign companies won the bid 10% of the company[EB/OL].(2021-06-24)[2021-12-22]. https://www.thepaper.cn/newsDetail_forward_13274064.

[7] Li Shouxi, Shen Tingzhi. A study on the effect of implementing drug procurement policy in China analysis of the impact on the performance and innovation ability of pharmaceutical enterprises[J]. Price Theory and Practice, 2020 (11): 49-52+97.

[8] Zhang Ling. Hengrui lost more than 2.5 billion sales based on the fifth batch of drug procurement results[EB/OL].(2021-06-24)[2021-12-22]. http://www.qq.com.

[9] Xiao Bei reads finance. Interpretation of Hengrui Medicine’s half-yearly report: To be good, to be fast, to be strong![EB/OL]. (2021-08-25)[2021-12-22]. https://xueqiu.com/1830902728/195323945.

[10] Shanghai Sunshine Pharmaceutical Procurement Network. Announcement on the inclusion of North China Pharmaceutical Co., Ltd. in the list of violations[EB/OL].(2021-08-20)[2022-01-22]. http://www.smpaa.cn/gjsdcg/2021/08/20/10254.shtml.